🔗 Permalink

Inventor profile of:

Peter Matthiessen

City:

Vienna

Country:

Austria

Published Applications:

21

Last publication date:

2025-03-27

Top Assignees for applications by Peter Matthiessen

The entities that hold a legal rights for patent applications filed by inventor Matthiessen Peter:

BAXTER INTERNATIONAL INC. 11 Deerfield, IL United States
BAXTER HEALTHCARE S.A. 8 Glattpark (Opfikon), Switzerland
BAXALTA INCORPORATED 7 Bannockburn, IL United States
BAXALTA GMBH 4 Glattpark (Opfikon), Switzerland
Takeda Pharmaceutical Company Limited 4 Osaka, Japan
Baxalta GmbH 3 Zug, Switzerland
Baxter Healthcare S.A. 2 Wallisellen, Switzerland
BAXALTA GMBH 2 Glattpark, Switzerland
Baxter Healthcasre S.A. 1 Glattpark (Opfikon), Switzerland
TAKEDA PHARMACEUTICAL COMAPANY LIMITED 1 OSAKA, Japan
Baxter Healthcare S.A. 1 Glattpark (Opfikon), -
Baxalta Incorporated 1 Bannockbum, Israel
Baxter Healthcare SA 1 Glattpark(Opfikon), Switzerland
BAXALTA GMBH 1 , Switzerland
Baxter Intermational Inc. 1 Deerfield, IL United States

Recent patent applications by Matthiessen Peter

Peter Matthiessen from Vienna, AT has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-03-27

US20250099559A1

Human necessities

STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS

#2 | 2023-04-27

US20230130866A1

Human necessities

Stabilized liquid and lyophilized ADAMTS13 formulations

#3 | 2020-12-03

US20200376098A1

Human necessities

Stabilized liquid and lyophilized ADAMTS13 formulations

#4 | 2019-08-15

US20190247475A1

Human necessities

Stabilized liquid and lyophilized ADAMTS13 formulations

#5 | 2018-07-26

US20180207245A1

Human necessities

Stabilized liquid and lyophilized ADAMTS13 formulations

#6 | 2017-04-27

US20170112906A1

Human necessities

Stabilized liquid and lyophilized ADAMTS13 formulations

#7 | 2016-12-29

US20160375111A1

Human necessities

Stabilized liquid and lyophilized ADAMTS13 formulations

#8 | 2015-08-06

US20150216983A1

Human necessities

Recombinant VWF formulations

#9 | 2014-10-16

US20140309176A1

Chemistry; metallurgy

Ethanol dependence of alpha1 antitrypsin C-terminal Lys truncation by basic carboxypeptidases

#10 | 2014-06-26

US20140178357A1

Human necessities

Stabilized liquid and lyophilized ADAMTS13 formulations

#11 | 2013-07-04

US20130171671A1

Chemistry; metallurgy

Methods for modeling protein stability

#12 | 2013-05-16

US20130119265A1

Human necessities

METHODS FOR THE INACTIVATION OF MIRCROORGANISMS IN BIOLOGICAL FLUIDS, FLOW THROUGH REACTORS AND METHODS OF CONTROLLING THE LIGHT SUM DOSE TO EFFECTIVELY INACTIVATE MICROORGANISMS IN BATCH REACTORS

#13 | 2013-05-09

US20130115204A1

Chemistry; metallurgy

PREPARATIVE PURIFICATION PROCESS FOR HUMAN FURIN

#14 | 2011-09-22

US20110229455A1

Human necessities

Stabilized liquid and lyophilized ADAMTS13 formulations

#15 | 2011-08-25

US20110206554A1

Human necessities

Methods for the inactivation of microorganisms in biological fluids, flow through reactors and methods of controlling the light sum dose to effectively inactivate microorganisms in batch reactors

#16 | 2009-12-10

US20090304669A1

Chemistry; metallurgy

Preparative purification process for human furin

#17 | 2009-07-30

US20090192076A1

Human necessities

RECOMBINANT VWF FORMULATIONS

#18 | 2007-11-29

US20070274976A1

Chemistry; metallurgy

Ethanol dependence of alpha1 antitrypsin C-terminal lys truncation by basic carboxypeptidases

#19 | 2007-02-15

US20070037270A1

Chemistry; metallurgy

Method for the purification of alpha-1 proteinase inhibitor (a1PI)

#20 | 2006-11-16

US20060257877A1

Method for the validatable inactivation of pathogens in a biological fluid by irradiation

#21 | 2006-03-02

US20060045796A1

Human necessities

Methods for the inactivation of microorganisms in biological fluids, flow through reactors and methods of controlling the light sum dose to effectively inactivate microorganisms in batch reactors

InventorID:

234113 ⎘